Roche subsidiary Genentech struck a multi‑year discovery collaboration with Caris Life Sciences to identify drug targets in solid tumors. The pact includes upfront and near‑term payments to Caris along with up to $1.1 billion in potential milestones and royalties tied to successful products. Genentech will leverage Caris’s molecular profiling and biomarker datasets to accelerate translational work and candidate selection for oncology programs, reflecting continued year‑end dealmaking momentum across biopharma.